HIV Preexposure Prophylaxis Utilization and Reasons for Never Using Preexposure Prophylaxis Among Transfeminine Persons in the United States: Findings From the Transgender Women’s Internet Survey and Testing (TWIST) Study
Duygu Islek(Emory University), Vani Vannappagari, Jennifer L. Glick(Louisiana State University Health Sciences Center New Orleans), Mariah Valentine-Graves(Emory University), Leigh Ragone(Research Triangle Park Foundation), Annemiek de Ruiter(ViiV Healthcare (Spain)), Savannah Winter(Emory University), Irah Lucas(Emory University), Supriya Sarkar, Travis Sanchez(Emory University), Stefan Baral(Johns Hopkins University), Joanna A. Caldwell(Emory University)
Cited by 1
Related Papers
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
|AIDS|2014|397
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
|AIDS|2002|359
A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population
|Infectious Diseases and Therapy|2018|197